- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
Consun Pharmaceutical Group
Market Cap: HK$12.8b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$15.18
7D
0.7%
1Y
82.9%
Akeso
Market Cap: HK$106.1b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$115.20
7D
-6.0%
1Y
65.8%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$102.0b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$437.60
7D
-4.5%
1Y
121.7%
InnoCare Pharma
Market Cap: HK$27.2b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$13.84
7D
-1.7%
1Y
96.0%
Simcere Pharmaceutical Group
Market Cap: HK$32.4b
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
2096
HK$12.48
7D
-4.7%
1Y
73.3%
CanSino Biologics
Market Cap: HK$14.9b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$42.48
7D
-2.1%
1Y
63.4%
RemeGen
Market Cap: HK$51.9b
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
9995
HK$84.55
7D
-8.4%
1Y
491.3%
Innovent Biologics
Market Cap: HK$146.6b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$85.55
7D
-1.5%
1Y
93.3%